NorayBio Licenses Noraynet to BioDynamics | GenomeWeb
NEW YORK (GenomeWeb News) - NorayBio licensed its biopharmaceutical platform to BioDynamics, NorayBio said today.
 
The platform, Noraymet ADME, predicts human pharmacokinetic models of new compounds from in vitro ADME data.
 
NorayBio has licensed the product to Spain's Faes Farma and Finland's Novamass.
 
NorayBio and BioDynamics also plan to co-develop software based on Noraymet ADME to refine human pharmacokinetic modelling.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.